BR0012787A - Agonistas de receptor de nicotina no recrutamento de célula tronco e de célula progenitora - Google Patents

Agonistas de receptor de nicotina no recrutamento de célula tronco e de célula progenitora

Info

Publication number
BR0012787A
BR0012787A BR0012787-6A BR0012787A BR0012787A BR 0012787 A BR0012787 A BR 0012787A BR 0012787 A BR0012787 A BR 0012787A BR 0012787 A BR0012787 A BR 0012787A
Authority
BR
Brazil
Prior art keywords
recruitment
cell
nicotine
receptor agonists
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
BR0012787-6A
Other languages
English (en)
Inventor
John Cooke
James Jang
Phillip Tsao
Frances Lauri Johnson
Anjali Pathak
Christopher Heeschen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stanford Leland Jr University Trustees
Original Assignee
Stanford Leland Jr University Trustees
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanford Leland Jr University Trustees filed Critical Stanford Leland Jr University Trustees
Publication of BR0012787A publication Critical patent/BR0012787A/pt
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"AGONISTAS DE RECEPTOR DE NICOTINA NO RECRUTAMENTO DE CéLULA TRONCO E DE CéLULA PROGENITORA". A presente invenção caracteriza métodos para o recrutamento de células tronco derivadas da medula óssea (por exemplo, precursores de célula endotelial, células tronco hematopoiéticas), pela administração de nicotina ou de um outro agonista de receptor de nicotina. Os métodos da invenção podem ser usados, por exemplo, no tratamento de condições receptivas a um tratamento por recrutamento de células tronco derivadas da medula óssea (por exemplo, neutropenia) . A figura é um gráfico que mostra a densidade de capilar (capilares / miócito) e a percentagem de novos vasos incorporando as células progenitoras endoteliais, para os animais de controle com salina e para os animais tratados com nicotina.
BR0012787-6A 1999-07-28 2000-07-28 Agonistas de receptor de nicotina no recrutamento de célula tronco e de célula progenitora Withdrawn BR0012787A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14623399P 1999-07-28 1999-07-28
US18830000P 2000-03-10 2000-03-10
PCT/US2000/020724 WO2001008683A1 (en) 1999-07-28 2000-07-28 Nicotine receptor agonists in stem cell and progenitor cell recruitment

Publications (1)

Publication Number Publication Date
BR0012787A true BR0012787A (pt) 2002-07-30

Family

ID=26843696

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012787-6A Withdrawn BR0012787A (pt) 1999-07-28 2000-07-28 Agonistas de receptor de nicotina no recrutamento de célula tronco e de célula progenitora

Country Status (9)

Country Link
US (1) US6720340B1 (pt)
EP (1) EP1207879B1 (pt)
JP (2) JP2003505506A (pt)
AT (1) ATE440602T1 (pt)
AU (1) AU778386B2 (pt)
BR (1) BR0012787A (pt)
CA (1) CA2380052C (pt)
DE (1) DE60042828D1 (pt)
WO (1) WO2001008683A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838539B2 (en) 1999-07-28 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Nicotine receptor agonists in stem cell and progenitor cell recruitment
WO2004012674A2 (en) * 2002-08-02 2004-02-12 Nutraceutical Development Corporation Development of muscle mass in a mammal
WO2005107817A2 (en) 2004-04-30 2005-11-17 Orbus Medical Technologies, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
WO2007075720A2 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses thereof
US8298528B2 (en) * 2006-04-17 2012-10-30 Hepacore Ltd. Methods for bone regeneration using endothelial progenitor cell preparations
ES2629086T3 (es) * 2006-10-30 2017-08-07 Genomix Co., Ltd. Sustancia farmacéutica para promover la regeneración funcional de tejido dañado
US8440617B2 (en) * 2007-03-22 2013-05-14 The Trustees Of The University Of Pennsylvania Hyperbaric treatment in wound healing
AU2009240884B8 (en) 2008-04-30 2014-03-06 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
RU2571230C2 (ru) 2008-04-30 2015-12-20 Дженомикс Ко., Лтд. Способ сбора функциональных клеток in vivo с высокой эффективностью
CN104825491A (zh) 2009-10-28 2015-08-12 吉诺米克斯股份有限公司 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
DK2703487T3 (en) 2011-04-26 2018-09-10 Genomix Co Ltd TIME TO INDUCTION Tissue Regeneration and its Use
AU2013335684B2 (en) 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
JP6253590B2 (ja) 2012-10-25 2017-12-27 株式会社ジェノミックス Ｈｍｇｂ１断片を利用した脊髄の損傷に対する新規治療法
EP3052119B1 (en) 2013-10-01 2018-08-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
CN106232800B (zh) 2014-03-25 2020-07-03 泰尔茂比司特公司 介质的被动替代
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
JP7182162B2 (ja) 2017-01-27 2022-12-02 株式会社ステムリム 心筋症、陳旧性心筋梗塞および慢性心不全の治療薬
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN110612344B (zh) 2017-03-31 2023-09-12 泰尔茂比司特公司 细胞扩增
WO2019107530A1 (ja) 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321387A (en) 1980-03-21 1982-03-23 Philip Morris, Incorporated Process for the preparation of optically active nicotine analogs
US4452984A (en) 1981-01-29 1984-06-05 Philip Morris, Inc. Optically active nicotine analogs and process for their preparation
US4332945A (en) 1981-01-29 1982-06-01 Philip Morris, Incorporated Optically active nicotine analogs and process for their preparation
US4442292A (en) 1981-01-29 1984-04-10 Philip Morris Incorporated Optically active nicotine analogs and process for their preparation
US4590278A (en) 1981-01-29 1986-05-20 Philip Morris Incorporated Nicotine analogs
GB8330969D0 (en) 1983-11-21 1983-12-29 Wellcome Found Promoting healing
US4920989A (en) 1985-04-25 1990-05-01 Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US5318957A (en) 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
US5766948A (en) * 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
US5508030A (en) 1993-08-05 1996-04-16 Bierman; Howard R. Creating new capillary blood pools for practicing bidirectional medicine
US5830651A (en) * 1995-06-01 1998-11-03 Signal Pharmaceuticals, Inc. Human oligodendroglial progenitor cell line
AU2340397A (en) * 1996-03-21 1997-10-10 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
US5869037A (en) 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
US5866561A (en) 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis
AU1214900A (en) * 1998-10-20 2000-05-08 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation

Also Published As

Publication number Publication date
EP1207879A4 (en) 2004-05-12
DE60042828D1 (de) 2009-10-08
EP1207879B1 (en) 2009-08-26
WO2001008683A1 (en) 2001-02-08
CA2380052C (en) 2007-10-23
US6720340B1 (en) 2004-04-13
CA2380052A1 (en) 2001-02-08
ATE440602T1 (de) 2009-09-15
JP2008291040A (ja) 2008-12-04
JP2003505506A (ja) 2003-02-12
AU778386B2 (en) 2004-12-02
AU6502600A (en) 2001-02-19
EP1207879A1 (en) 2002-05-29

Similar Documents

Publication Publication Date Title
BR0012787A (pt) Agonistas de receptor de nicotina no recrutamento de célula tronco e de célula progenitora
Novalija et al. Sevoflurane mimics ischemic preconditioning effects on coronary flow and nitric oxide release in isolated hearts
Kume et al. Beta-adrenergic agonists regulate KCa channels in airway smooth muscle by cAMP-dependent and-independent mechanisms.
Brown et al. Adrenergic and cholinergic regulation of lung surfactant secretion in the isolated perfused rat lung and in the alveolar type II cell in culture.
Perregaux et al. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity.
BR0113680A (pt) Dispositivo cirúrgico percutâneo e método para criar uma cavidade em osso
MALING et al. Species differences in aortic responses to vasoactive amines: The effects of compound 48/80, cocaine, reserpine and 6-hydroxydopamine
Goss Experimental investigations of morphogenesis in the growing antler
Tiaho et al. Regulation of the frequency‐dependent facilitation of L‐type Ca2+ currents in rat ventricular myocytes.
Hill et al. Angiogenic factor in vitreous from diabetic retinopathy
Boutros et al. Isoflurane and halothane increase adenosine triphosphate preservation, but do not provide additive recovery of function after ischemia, in preconditioned rat hearts
Featherstone et al. Comparison of phosphodiesterase inhibitors of differing isoenzyme selectivity added to St. Thomas' hospital cardioplegic solution used for hypothermic preservation of rat lungs
Soltan et al. Bone grafting by means of a tunnel dissection: predictable results using stem cells and matrix
Dutton Variations in glucuronide formation by perinatal liver
Florey The clam-heart bioassay for acetylcholine
Darcus A person's relation to φρήν in Homer, Hesiod, and the Greek lyric poets
Hay et al. Comparison of endothelin B (ETB) receptors in rabbit isolated pulmonary artery and bronchus
Pelster Structure and function of the external gill filaments of embryonic skates (Raja erinacea)
Rodgers et al. Elevated cyclic GMP concentrations in rabbit bone marrow culture and mouse spleen following erythropoietic stimulation
Macdonald Aberrant growth of maxillary canine teeth in male babirusa (genus Babyrousa)
Hissa et al. Development of temperature regulation in newborn reindeer
Liu et al. The role of prostaglandins and the hypothalamus in thermoregulation in the lizard, Phrynocephalus przewalskii (Agamidae)
Edström et al. Metabolic and morphologic changes in brown adipose tissue from non‐growing mice with an isogeneic sarcoma. Evaluation with respect to development of cachexia
Goldring et al. Cells cultured from human giant cell tumors of bone respond to parathyroid hormone
Inoki et al. The cholinergic system and the dental pulp

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.